Erasca, Inc. Share Price & Technical Analysis
ERAS · $11.27 (+0.27%)
Healthcare / Biotechnology
$11.27
+0.27%
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid t…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
8% return in May, 5% avg return in past 3 year May month.
208% return in 2026, 15% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 184% | 30% | 22% | -35% | 8% | – | – | – | – | – | – | – | 208% |
| 25 | -27% | -26% | 0% | 7% | -7% | -7% | 8% | 14% | 38% | 9% | 28% | 16% | 52% |
| 24 | -23% | 41% | -12% | -5% | 25% | -4% | 39% | -6% | -4% | -4% | 12% | -11% | 48% |
| 23 | -7% | -10% | -17% | -7% | -4% | 4% | -4% | 0% | -23% | 15% | -26% | 24% | -55% |
| 22 | -23% | 4% | -30% | -16% | -25% | 4% | 36% | 22% | -8% | 5% | -8% | -43% | -83% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.15B
P/E ratio
—
52W high
$24.28
52W low
$1.06
Volume
11,63,930
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Erasca, Inc. share price today?
- Erasca, Inc. (ERAS) last traded around $11.27 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ERAS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ERAS. Download the app for real-time alerts.
- How can I analyze Erasca, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.